High IL-17E and Low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Lonati, Paola Adele ^a,b   Brembilla, Nicolò Costantino ^a   Montanari, Elisa ^a   Fontao, Lionel ^a   Gabrielli, Armando ^c   Vettori, Serena ^d   Valentini, Gabriele ^d   Laffitte, Emmanuel ^a   Kaya, Gurkan ^a   Meroni, Pier Luigi ^b,e   Chizzolini, Carlo ^a  

^a University Hospital and Faculty of Medicine   (Switzerland)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Dermatology University Hospital and School of Medicine ^*  (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 25; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL25 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MORPHEA; PATHOGENESIS; PLASTIC SURGERY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; CASE CONTROL STUDY; CELL CULTURE; FIBROBLAST; FIBROSIS; LOCALIZED SCLERODERMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; DERMIS; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84929941003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105008     Document Type: Article

References (38)

1. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360: 1989-2003.
2. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME (2011) Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 10: 276-281.
3. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, et al. (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71: 1355-1360.
4. Yaqub A, Chung L, Rieger KE, Fiorentino DF (2013) Localized cutaneous fibrosing disorders. Rheum Dis Clin North Am 39: 347-364.
5. Chung L, Lin J, Furst DE, Fiorentino D (2006) Systemic and localized scleroderma. Clin Dermatol 24: 374-392. (Pubitemid 44332868)
6. Torres JE, Sanchez JL (1998) Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 20: 242-245. (Pubitemid 28274917)
7. Limpers A, van Royen-Kerkhof A, van Roon JA, Radstake T, Broen JC (2014) Overlapping gene expression profiles indicative of antigen processing and the interferon pathway characterize inflammatory fibrotic skin diseases. Expert Rev Clin Immunol 10: 231-241.
8. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207: 535-552.
9. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, et al. (2011) IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 6: e23185.
10. Mi S, Li Z, Yang HZ, Liu H, Wang JP, et al. (2011) Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 187: 3003-3014.
11. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, et al. (2012) Potential roles of interleukin 17A in the development of skin fibrosis. Arthritis Rheum: doi: 10.1002/art.34643.
12. Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, et al. (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 4: e5903.
13. Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 13: R166.
14. Meloni F, Solari N, Cavagna L, Morosini M, Montecucco CM, et al. (2009) Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 27: 765-772.
15. Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, et al. (2013) Interleukin-17A+ cells are increased in systemic sclerosis skin and their number is inversely correlated to the extent of skin involvement. Arthritis Rheum.
16. Brembilla NC, Chizzolini C (2013) T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw.
17. Agarwal S, Misra R, Aggarwal A (2008) Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 35: 515-519. (Pubitemid 351374430)
18. Cortez DM, Feldman MD, Mummidi S, Valente AJ, Steffensen B, et al. (2007) IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 293: H3356-3365. (Pubitemid 350230876)
19. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, et al. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593-2603. (Pubitemid 26193037)
20. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, et al. (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43: 2455-2463.
21. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, et al. (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155: 5483-5486.
22. Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, et al. (2013) Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 15: R151.
23. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, et al. (2012) Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts. J Immunol.
24. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9: 556-567.
25. Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71: 1-8. (Pubitemid 34062767)
26. Hayashi H, Kawakita A, Okazaki S, Yasutomi M, Murai H, et al. (2013) IL-17A/F modulates fibrocyte functions in cooperation with CD40-mediated signaling. Inflammation 36: 830-838.
27. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, et al. (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor. E. Immunity 35: 611-621.
28. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, et al. (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15: 985-995. (Pubitemid 34075378)
29. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KH, et al. (2013) IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 68: 82-90.
30. Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, et al. (2014) IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A 111: 367-372.
31. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205. (Pubitemid 18073738)
32. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, et al. (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48: 2593-2604. (Pubitemid 37129436)
33. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, et al. (2009) Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
34. Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, et al. (2009) Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. Immunity 31: 587-597.
35. Dharamsi JW, Victor S, Aguwa N, Ahn C, Arnett F, et al. (2013) Morphea in adults and children cohort III: nested case-control study-the clinical significance of autoantibodies in morphea. JAMA Dermatol 149: 1159-1165.
36. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, et al. (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 282: 13447-13455. (Pubitemid 47100510)
37. Pappu R, Rutz S, Ouyang W (2012) Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol 33: 343-349.
38. Medsger TA, Steen VD (1996) Classification and prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis Baltimore: Williams and Wilkins. pp. 51-64.